Orthocell has today reached a critical milestone in the commercialisation of Remplir\u2122 in the US$1.6 Billion US market, recording its first sales revenue from the nerve repair product in the US.<\/p>\n
This revenue follows first surgical use of Remplir\u2122 on 26 June in Ohio and subsequent early surgical cases in Florida. Early-stage surgeries conducted in out-patient day surgeries, known as Ambulatory Surgery Centers in the US, play a crucial strategic role in building experience and knowledge amongst the US surgical community.<\/p>\n
Orthocell CEO and MD, Paul Anderson, said:<\/p>\n
\u201cTranslating Remplir\u2019s regulatory clearance in the US to first sales revenue in a little over three months is a testament to the hard work we\u2019ve done with our US roll out plan.\u00a0 This covers everything from our key internal hires in sales, marketing and medical affairs, appointing specialist distributors, Australian manufacturing ramp up and working with our on-the-ground US logistics partner\u2026. We are confident our efforts in the US are on track to drive growth in sales of Remplir during the second half of calendar 2025.\u201d<\/p>\n